NCT01484197 - A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Asthma

Interventions

DRUG

75 µg indacaterol maleate (LB)

75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.

DRUG

75 µg indacaterol maleate (PoS)

75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

DRUG

37.5 µg indacaterol maleate (PoS)

37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

DRUG

placebo to indacaterol (LB)

Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.

DRUG

placebo to indacaterol (PoS)

Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.

Trial Locations (2)

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Machester